<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701906</url>
  </required_header>
  <id_info>
    <org_study_id>PRE/18.02</org_study_id>
    <nct_id>NCT03701906</nct_id>
  </id_info>
  <brief_title>Effect of a Mixture of New Probiotic Strains in Preterm Infants</brief_title>
  <acronym>PREBIOMA</acronym>
  <official_title>Effect of a Mixture of New Probiotic Strains in the Colonization of the Gastrointestinal Tract of Preterm Infants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProbiSearch SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProbiSearch SL</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional, randomized, double-blind, placebo-controlled study will be conducted to
      investigate the effect of a new probiotic strain Lactobacillus PS11603 &amp; Bifidobacterium
      PS10402 in premature infants from 28 weeks + 0 days to 30 weeks + 6 days of gestation.

      The study duration will be 2 months, which includes 8 weeks product administration.
      Participants will be randomized assigned to one of the two study groups: the control group
      with placebo consumption and a probiotic consumption group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An interventional, randomized, double-blind, placebo-controlled study will be conducted to
      investigate the effect of a new probiotic strains Lactobacillus PS11603 &amp; Bifidobacterium
      PS10402 in 30 premature infants born within 28 weeks + 0 days to 30 weeks + 6 days of
      gestation.

      The duration of participation in the study is estimated to be 40-60 days. Participants will
      be randomized assigned to one of the two arms of the study: the control group, with placebo
      consumption, and a probiotic consumption group. The aim of the study will be investigate the
      effect of the probiotics strains in the colonization of the intestinal tract of preterm
      babies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an interventional, randomized, double-blind, placebo-controlled, parallel-group study.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Counts (CFU/g) of Bifidobacterium and Lactobacillus colonies from fecal samples.</measure>
    <time_frame>2 months</time_frame>
    <description>Counts (CFU/g) of Bifidobacterium and Lactobacillus presents in fecal samples from preterm infants</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Premature Infant</condition>
  <arm_group>
    <arm_group_label>Lactobacillus PS11603 &amp; Bifidobacterium PS10402</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus PS11603 and 1*10E8 CFU of Bifidobacterium PS10402 in 1 vial will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 vial of Placebo will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus PS11603 &amp; Bifidobacterium PS10402</intervention_name>
    <description>Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1*10E9 CFU of L.salivarius PS11603 and 1*10E8 CFU of B.longum PS10402.</description>
    <arm_group_label>Lactobacillus PS11603 &amp; Bifidobacterium PS10402</arm_group_label>
    <other_name>Lactobacillus PS11603 &amp; Bifidobacterium PS10402 during 8 weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm infants born between week 28 + 0 days and week 30 + 6 days of gestation.

          -  Written informed consent signed by the parent or legal guardian.

          -  Tolerate enteral feeding, at least 10mL / kg / day.

          -  Postnatal age â‰¤ 5 days

        Exclusion Criteria:

          -  Child with malformations

          -  With short bowel syndrome or any surgery in the gastrointestinal tract

          -  With defect in the intestinal epithelial barrier
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susana Manzano, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ProbiSearch SL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

